Cholangiocarcinoma News and Research

RSS
Redhill Biopharma announces completion of Phase 2/3 COVID-19 study of oral opaganib

Redhill Biopharma announces completion of Phase 2/3 COVID-19 study of oral opaganib

Antagonism of glucocorticoid receptors promotes apoptosis in solid tumor cells

Antagonism of glucocorticoid receptors promotes apoptosis in solid tumor cells

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

SWOG researchers to present practice-changing research at virtual ASCO 2021

SWOG researchers to present practice-changing research at virtual ASCO 2021

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

Combining PD-1 and VEGF inhibitors with chemotherapy can help control cholangiocarcinoma

Combining PD-1 and VEGF inhibitors with chemotherapy can help control cholangiocarcinoma

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

AACR and MPM award three grants to support groundbreaking cancer research projects

AACR and MPM award three grants to support groundbreaking cancer research projects

Researchers discover a new approach to inhibit intrahepatic cholangiocarcinoma

Researchers discover a new approach to inhibit intrahepatic cholangiocarcinoma

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

P2 COVID-19 study shows no material safety differences between opaganib and control arms

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

RedHill Biopharma announces promising preliminary results from opaganib study

RedHill Biopharma announces promising preliminary results from opaganib study

Combination therapy effective for patients with cholangiocarcinoma marked by BRAF mutations

Combination therapy effective for patients with cholangiocarcinoma marked by BRAF mutations

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

Changes in surface sugarlike molecules help cancer cells to spread

Changes in surface sugarlike molecules help cancer cells to spread

Bile duct cancer treatment could be improved by tailored medication

Bile duct cancer treatment could be improved by tailored medication

Study shows how treatment resistance develops in patients with bile duct cancer

Study shows how treatment resistance develops in patients with bile duct cancer

Data results of NCI-MATCH trial in tumors with DNA mismatch repair deficiencies

Data results of NCI-MATCH trial in tumors with DNA mismatch repair deficiencies